polypeptide N-acetylgalactosaminyltransferase like 6Genealiases: GALNACT20 · GALNT17 · GalNAc-T6L
Q-omics provides the consensus-scored GALNTL6 profile across patient tissues and cancer cell-line models. GALNTL6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GALNTL6 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, GALNTL6 RNA expression shows 16,024 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where GALNTL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNTL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNTL6 survival associations across molecular data types. GALNTL6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNTL6 RNA expression–survival associations across cancer types. High GALNTL6 expression shows unfavorable associations in KIRC, KIRP and SKCM, but favorable associations in BRCA, LGG and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GALNTL6 RNA expression.
This table summarizes GALNTL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GALNTL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNTL6 shows lower tumor expression in KIRC and higher tumor expression in THCA, COAD, BRCA, KICH and PRAD. The THCA box plot shows higher GALNTL6 RNA expression in tumor versus normal tissue (log2 FC = +0.771, t-test p < 0.001).
This table shows molecular features associated with GALNTL6 in patient tissues and cancer cell lines. In patient samples, GALNTL6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNTL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
